Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

2.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM.

Endocr Pract. 2010 Nov-Dec;16(6):1016-9. No abstract available.

3.

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.

Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM; FLEX Research Group..

J Bone Miner Res. 2010 May;25(5):976-82. doi: 10.1002/jbmr.11.

4.

Long-term use of bisphosphonates in osteoporosis.

Watts NB, Diab DL.

J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Review.

PMID:
20173017
5.

Deaths: final data for 2006.

Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B.

Natl Vital Stat Rep. 2009 Apr 17;57(14):1-134.

6.

Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

Tosteson AN, Burge RT, Marshall DA, Lindsay R.

Am J Manag Care. 2008 Sep;14(9):605-15.

7.

United States life tables, 2004.

Arias E.

Natl Vital Stat Rep. 2007 Dec 28;56(9):1-39.

8.
9.

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group..

JAMA. 2006 Dec 27;296(24):2927-38.

PMID:
17190893
10.

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A.

J Bone Miner Res. 2007 Mar;22(3):465-75.

11.

Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores.

Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG.

Med Decis Making. 2006 Jul-Aug;26(4):391-400.

PMID:
16855127
12.

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.

Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM.

Arch Intern Med. 2006 Jun 12;166(11):1209-17.

PMID:
16772249
13.

Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis.

Nayak S, Olkin I, Liu H, Grabe M, Gould MK, Allen IE, Owens DK, Bravata DM.

Ann Intern Med. 2006 Jun 6;144(11):832-41.

PMID:
16754925
14.

Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.

North American Menopause Society..

Menopause. 2006 May-Jun;13(3):340-67; quiz 368-9.

PMID:
16735931
15.

Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.

Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK.

Med Decis Making. 2006 Mar-Apr;26(2):194-206.

PMID:
16525173
16.

Compliance with osteoporosis medications.

Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA.

Arch Intern Med. 2005 Nov 14;165(20):2414-9.

PMID:
16287772
17.

Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.

Schousboe JT, Ensrud KE, Nyman JA, Melton LJ 3rd, Kane RL.

J Am Geriatr Soc. 2005 Oct;53(10):1697-704.

PMID:
16181168
18.

Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.

Recker RR, Gallagher R, MacCosbe PE.

Mayo Clin Proc. 2005 Jul;80(7):856-61.

PMID:
16007889
19.

Economic comparison of diagnostic approaches for evaluating osteoporosis in older women.

Kraemer DF, Nelson HD, Bauer DC, Helfand M.

Osteoporos Int. 2006 Jan;17(1):68-76.

PMID:
15889313
20.

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.

Schousboe JT, Nyman JA, Kane RL, Ensrud KE.

Ann Intern Med. 2005 May 3;142(9):734-41.

PMID:
15867405
Items per page

Supplemental Content

Support Center